Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$698.05
-3.18-0.45%
al cierre: -
$696.35
-1.70-0.24%
After hour: 7:54 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Eli Lilly and Co ha un obiettivo di prezzo di consenso pari a $941.19, stabilito in base alle ultime valutazioni degli analisti di 28. Le ultime 3 valutazioni degli analisti sono state rilasciate da Cantor Fitzgerald, Guggenheim y Deutsche Bank il agosto 13, 2025, agosto 13, 2025 y agosto 11, 2025. Con un obiettivo di prezzo medio di $866.67 tra le Cantor Fitzgerald, Guggenheim y Deutsche Bank, c'è un implicito 24.46% upside per Eli Lilly and Co da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Cantor Fitzgerald
Guggenheim
Deutsche Bank
JP Morgan
UBS
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Eli Lilly
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/13/2025 | 18.47% | Cantor Fitzgerald | $975 → $825 | Maintains | Overweight | |||
08/13/2025 | 25.66% | Guggenheim | $942 → $875 | Maintains | Buy | |||
08/11/2025 | 29.25% | Deutsche Bank | $1010 → $900 | Maintains | Buy | |||
08/08/2025 | 57.97% | JP Morgan | $1100 → $1100 | Reiterates | Overweight → Overweight | |||
08/08/2025 | 28.53% | UBS | $1050 → $895 | Maintains | Buy | |||
07/11/2025 | 35.28% | Guggenheim | $936 → $942 | Maintains | Buy | |||
07/10/2025 | 62.99% | Morgan Stanley | $1133 → $1135 | Maintains | Overweight | |||
06/20/2025 | 34.42% | Guggenheim | $936 → $936 | Reiterates | Buy → Buy | |||
05/02/2025 | 50.79% | UBS | $1100 → $1050 | Maintains | Buy | |||
04/28/2025 | 0.52% | HSBC | $1150 → $700 | Downgrade | Buy → Reduce | |||
04/22/2025 | 40.02% | Cantor Fitzgerald | → $975 | Initiates | → Overweight | |||
04/14/2025 | 33.27% | Guggenheim | $973 → $928 | Maintains | Buy | |||
04/09/2025 | 61.41% | Morgan Stanley | $1146 → $1124 | Maintains | Overweight | |||
04/08/2025 | 27.52% | Goldman Sachs | $892 → $888 | Upgrade | Neutral → Buy | |||
03/05/2025 | 57.97% | Wells Fargo | $970 → $1100 | Maintains | Overweight | |||
02/03/2025 | 49.06% | Truist Securities | $1029 → $1038 | Maintains | Buy | |||
01/28/2025 | 39.3% | Wells Fargo | $1000 → $970 | Maintains | Overweight | |||
01/28/2025 | 70.89% | Citigroup | $1250 → $1190 | Maintains | Buy | |||
12/10/2024 | 43.18% | B of A Securities | → $997 | Reinstates | → Buy | |||
11/15/2024 | 43.61% | Wolfe Research | → $1000 | Initiates | → Outperform | |||
11/04/2024 | 45.76% | Deutsche Bank | $1025 → $1015 | Maintains | Buy | |||
10/31/2024 | 40.02% | Barclays | $1025 → $975 | Maintains | Overweight | |||
10/31/2024 | 57.97% | B of A Securities | $1150 → $1100 | Maintains | Buy | |||
10/25/2024 | 79.51% | Citigroup | $1060 → $1250 | Maintains | Buy | |||
10/17/2024 | 57.97% | Bernstein | — | → $1100 | Initiates | → Outperform | ||
10/10/2024 | 48.34% | Truist Securities | $1000 → $1033 | Maintains | Buy | |||
10/03/2024 | 47.2% | Deutsche Bank | $1025 → $1025 | Reiterates | Buy → Buy | |||
09/16/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
09/13/2024 | 57.97% | JP Morgan | $1050 → $1100 | Maintains | Overweight | |||
09/13/2024 | 52.22% | Citigroup | → $1060 | Reinstates | Buy → Buy | |||
09/09/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
08/27/2024 | 58.83% | Morgan Stanley | $1106 → $1106 | Reiterates | Overweight → Overweight | |||
08/19/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
08/16/2024 | 47.91% | Guggenheim | $884 → $1030 | Maintains | Buy | |||
08/14/2024 | 50.79% | Berenberg | $1000 → $1050 | Maintains | Buy | |||
08/12/2024 | 47.2% | Deutsche Bank | $725 → $1025 | Upgrade | Hold → Buy | |||
08/09/2024 | 43.61% | Wells Fargo | $875 → $1000 | Maintains | Overweight | |||
08/09/2024 | 58.11% | BMO Capital | $1001 → $1101 | Maintains | Outperform | |||
08/09/2024 | 61.56% | B of A Securities | $1000 → $1125 | Maintains | Buy | |||
08/05/2024 | 26.95% | Guggenheim | $855 → $884 | Maintains | Buy | |||
08/05/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/24/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/15/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/11/2024 | 43.61% | Berenberg | $850 → $1000 | Maintains | Buy | |||
07/11/2024 | 43.61% | JP Morgan | $900 → $1000 | Maintains | Overweight | |||
07/10/2024 | 47.2% | Barclays | $913 → $1025 | Maintains | Overweight | |||
07/05/2024 | 46.91% | Morgan Stanley | $1023 → $1023 | Maintains | Overweight | |||
07/03/2024 | 43.75% | BMO Capital | $1001 → $1001 | Maintains | Outperform | |||
07/01/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/26/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 43.61% | Truist Securities | $892 → $1000 | Reiterates | Buy → Buy | |||
06/24/2024 | 45.76% | Jefferies | $994 → $1015 | Maintains | Buy | |||
06/24/2024 | 43.61% | B of A Securities | $1000 → $1000 | Maintains | Buy | |||
06/24/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/20/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/17/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/12/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/11/2024 | 27.09% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/07/2024 | 37.43% | Jefferies | $925 → $957 | Maintains | Buy | |||
05/14/2024 | 20.63% | Argus Research | $770 → $840 | Maintains | Buy | |||
05/01/2024 | 43.75% | BMO Capital | $900 → $1001 | Maintains | Outperform | |||
05/01/2024 | 29.25% | JP Morgan | $850 → $900 | Maintains | Overweight | |||
05/01/2024 | 27.09% | Cantor Fitzgerald | $815 → $885 | Maintains | Overweight | |||
05/01/2024 | 28.1% | Truist Securities | $850 → $892 | Maintains | Buy | |||
04/30/2024 | 27.09% | Cantor Fitzgerald | $815 → $885 | Reiterates | Overweight → Overweight | |||
04/18/2024 | 17.04% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/15/2024 | 17.04% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/11/2024 | 3.83% | Goldman Sachs | $650 → $723 | Maintains | Neutral | |||
04/05/2024 | 17.04% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/03/2024 | — | Erste Group | — | Upgrade | Hold → Buy | |||
04/02/2024 | 28.53% | Citigroup | $675 → $895 | Maintains | Buy | |||
04/01/2024 | 17.04% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
03/22/2024 | 22.07% | Truist Securities | → $850 | Reiterates | Buy → Buy | |||
03/15/2024 | 22.07% | JP Morgan | $775 → $850 | Maintains | Overweight | |||
03/01/2024 | 43.61% | B of A Securities | $800 → $1000 | Maintains | Buy | |||
02/21/2024 | 17.76% | DZ Bank | → $820 | Downgrade | Buy → Hold | |||
02/20/2024 | 17.04% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
02/16/2024 | 36.43% | Morgan Stanley | $805 → $950 | Maintains | Overweight | |||
02/14/2024 | 17.04% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
02/07/2024 | 16.32% | Barclays | $680 → $810 | Maintains | Overweight | |||
02/07/2024 | 22.07% | Truist Securities | $650 → $850 | Maintains | Buy | |||
02/07/2024 | 15.6% | Morgan Stanley | $763 → $805 | Maintains | Overweight | |||
02/07/2024 | 18.47% | Wells Fargo | $700 → $825 | Maintains | Overweight | |||
02/07/2024 | 24.22% | BMO Capital | $710 → $865 | Maintains | Outperform | |||
02/06/2024 | 18.47% | Wells Fargo | $700 → $825 | Maintains | Overweight | |||
02/06/2024 | 17.04% | Cantor Fitzgerald | $630 → $815 | Maintains | Overweight | |||
02/05/2024 | -9.53% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
02/01/2024 | -9.53% | Cantor Fitzgerald | $630 → $630 | Reiterates | Overweight → Overweight | |||
01/24/2024 | 0.52% | Wells Fargo | $650 → $700 | Maintains | Overweight | |||
01/23/2024 | -9.53% | Cantor Fitzgerald | $630 → $630 | Reiterates | Overweight → Overweight | |||
01/23/2024 | -2.35% | Barclays | $630 → $680 | Maintains | Overweight | |||
12/21/2023 | -12.4% | Daiwa Capital | → $610 | Downgrade | Buy → Outperform | |||
11/29/2023 | -6.66% | Truist Securities | → $650 | Reiterates | Buy → Buy | |||
11/20/2023 | -9.53% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
11/17/2023 | -9.53% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
11/15/2023 | -9.53% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
11/09/2023 | -23.17% | Deutsche Bank | → $535 | Initiates | → Hold | |||
11/08/2023 | — | JP Morgan | — | Reiterates | → Overweight | |||
11/03/2023 | 3.68% | Morgan Stanley | $673 → $722 | Maintains | Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Eli Lilly (LLY)?
El último precio objetivo de Eli Lilly (NYSE:LLY) fue comunicado por Cantor Fitzgerald el agosto 13, 2025. La firma de analistas fijó un precio objetivo para $825.00 que espera LLY a rise dentro de 12 meses (un posible 18.47% upside). 32 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Eli Lilly (LLY)?
La última calificación de analistas para Eli Lilly (NYSE:LLY) fue proporcionada por Cantor Fitzgerald, y Eli Lilly mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Eli Lilly (LLY)?
La última revisión al alza de Eli Lilly and Co se produjo en abril 8, 2025, cuando Goldman Sachs elevó su precio objetivo a $888. Goldman Sachs anteriormente tenía a neutral para Eli Lilly and Co.
¿Cuándo fue la última revisión a la baja de Eli Lilly (LLY)?
La última revisión a la baja de Eli Lilly and Co se produjo en abril 28, 2025, cuando HSBC cambió su precio objetivo de $1150 a $700 para Eli Lilly and Co.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Eli Lilly (LLY)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Eli Lilly, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Eli Lilly se registró el agosto 13, 2025, por lo que la próxima calificación estará disponible en torno al agosto 13, 2026.
¿Es correcta la calificación de los analistas sobre Eli Lilly (LLY)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Eli Lilly (LLY) fue un mantuvo con un precio objetivo de $975.00 a $825.00. El precio actual al que cotiza Eli Lilly (LLY) es de $696.35, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.